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SUMMARY
Purpose To compare the results of causality assessments of reported adverse drug reactions (ADR’s) obtained from deci-
sional algorithms with those obtained from an expert panel using the WHO global introspection method (GI) and to further
evaluate the influence of confounding variables on algorithms ability in assessing causality.
Method Two hundred sequentially reported ADR’s were included in this study. An independent researcher used algo-
rithms, while an expert panel assessed the same reports using the GI, both aimed at evaluating causality. Reports were
divided into three groups according to the presence, absence or lack of information on confounding variables.
Results For the total sample, observed agreements between decisional algorithms compared with GI varied from 21% to
56%, average of 47%. When confounding variables were taken into account, agreements varied between 41% and 69%,
average of 58%; 8% and 65%, average of 46% and 15% and 53%, average of 42% accordingly to the absence, lack of infor-
mation or presence of confounding variables, respectively. The extend of reproducibility beyond chance was low for the total
sample (average Kappa¼ 0.26) and within the groups considered.
Conclusion The overall observed agreement between algorithm and GI was moderate although poorly different from
chance, confounding variables being a shortcoming of algorithms ability in assessing causality. Copyright # 2005 John
Wiley & Sons, Ltd.
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INTRODUCTION
An adverse drug reaction is any noxious and unin-
tended response to a drug that occurs at doses nor-
mally used in man for prophylaxis, diagnosis,
therapy or modification of a physiological function.1
Causality assessment of identified adverse events
during drug exposure is crucial in pharmacovigiliance
activities due to its implications on the risk-benefit
ratio evaluations of medicines.
The ‘Nu´cleo de Farmacovigilncia do Centro’,
NFC—the central Portugal regional pharmaco-
vigilance unit—started the reception of ADR reports
from family physicians and community pharmacists in
January 2001. According to its regulatory responsi-
bilities, causality assessment of reported ADR’s is
mandatory. As a component of the adopted standard
operating procedures of the Portuguese pharmacov-
igilance system, the global introspection (GI) based on
the World Health Organisation scale of imputability2
has been used.
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Despite its usefulness, the GI method has been subject
to criticisms of subjectivity and imprecision since it is
mainly based on expert clinical judgements.3,4
Concurrently, but not alternatively, several decisional
algorithms have been published, combining, and scoring
different criteria as an explicit approach, claiming the
advantage of avoiding subjective bias.3–5 However, none
of the algorithms published since 1976 have been
universally accepted as a gold standard and several
studies pointed out disagreements between the results
obtained from the use of the different algorithms in
assessing causality for the same ADR reports.6–12
However, it should be emphasised that algorithms
were not designed and do not intent to replace medical
diagnosis.
This study was carried out to evaluate causality in
reported adverse drug reactions (ADR) using publ-
ished algorithms and to further compare the results
with those obtained by the consensus opinion of
specialist’s panel using the World Health Organisation
GI method in order to determine the usefulness of
algorithms on causality assessment of ADR.
METHODS
Two hundred sequentially reported ADR’s to the
NFC, 131 from general practitioners (GPs) and 69
from community pharmacists, from January 2001,
were studied. The sample included a large spectrum
of clinical events. For each ADR report, an average
of two clinical manifestations was described.
Twenty-seven percent of the reported ADR’s were
considered serious according to the WHO’s criteria.13
One hundred and forty eight different drugs were
reported as responsible for the suspected ADR’s. In
78% of the reports, concurrent medications were pre-
sent (maximum 7, average 2).
From a literature search on Pubmed using ‘pharma-
covigilance’, ‘imputability’, ‘algorithm’, ‘introspec-
tion’ and ‘adverse reaction’ mesh headings, the
following decisional algorithms published between
1970 and 2001 were identified:
Some algorithms were withdrawn from the study.
Adrian, Castle and Evreux algorithms, which present
results in numerical values were excluded due to the
lack of equivalence with causality terminology used in
the GI method. Bayesian, Lagier and Hoskins &
Mannino methods need aetiologic balance in causality
assessment, information not requested in filling
Portuguese ADR report forms. Algorithms aimed at
specific ADR’s were also withdrawn from the study—
hepatic toxicity (Maria V. and Stricker), teratogenicity
(Loupi) and predetermined disease states (RUCAM).
Finally, we excluded Jain, Taiwan and CPMP
approaches, which only have three levels for causality
assessment, therefore giving inconsistency in match-
ing results with the six levels of the GI method.
The following algorithms were then applied, all
supported by the combination of five common major
criteria for causality assessment: challenge, dechal-
lenge, rechallenge, previous bibliographic description
and etiologic alternatives.
An investigator independently assessed the causality
of the 200 adverse events using the decisional
algorithms. ADR’s reports were simultaneously and
independently assessed by an expert panel comprising
two clinical pharmacologists (one also being a
specialist in internal medicine), two pharmacists and
a general practitioner using the GI method based on the
World Health Organisation scale of imputability.2
Causality assessments produced from both modal-
ities were finally compared and analysed using the
kappa index of reliability. Epi Info 2002 software was
used for the analysis.
The terminology used to express causality was found
to be qualitatively and quantitatively different between
algorithms, therefore giving limitations to accurate
comparisons. In the light of such findings, a corre-
spondence table of terms from different algorithms was
developed (Table 1). Other correspondences between
terms were published,43,44 but so far they did not
include all the studied algorithms. According to the GI
method, there are six levels of imputation: certain/
definitive, probable, possible, unlikely, conditional
and unclassifiable. A drug-related event can only be
considered when one at the first three levels is found.
The equivalence of terms between the selected
algorithms and GI was based on the following
criteria:
AD, ADRIAN14 HM, Hoskins &
Mannino24
MV, Maria V.35
Aust, Australian15 HS, Hsu-Stoll25 N, Naranjo36
By, Bayesian16 I, Irey26 R, RUCAM37
B, Blanc4 Ja, Jain27 St, Stephens38
Ca, Castle17 Jo, Jones28 Sk, Stricker39
Co, Cornelli18 KL, Karch &
Lasagna5
T, Taiwan40
CPMP, ABO system19 Ki, Kitaguchi29 V, Venulet41
D, Dangoumau20,21 Kr, Kramer30–32 W, Weber42
Em, Emanueli22 La, Lagier33 WHO2
Ev, Evreux23 Lu, Loupi34
Aust, Australian15 HS, Hsu Stoll25 Kr, Kramer30–32
B, Blanc4 I, Irey26 N, Naranjo36
Co, Cornelli18 Jo, Jones28 St, Stephens38
D, Dangoumau 20,21 KL, Karch & Lasagna5 V, Venulet41
Em, Emanueli22 Ki, Kitaguchi29 W, Weber42
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When, for a given algorithm, a level of imputation
between ‘certain’ and ‘probable’ was present, causality
was considered as ‘probable’. The level of causality
‘possible’ was considered the lower limit of acceptance
of an adverse event as an adverse drug reaction. In
order to classify an adverse event as non-drug related,
the following terms were considered as equivalents,
since different terminologies are used with the same
meaning across the selected algorithms: ‘coinciden-
tal’, ‘conditional’, ‘excluded’, ‘general list’, ‘nega-
tive’, ‘remote’, ‘unclassifiable’, ‘unknown’, ‘unlikely’,
‘unrelated’ and ‘very doubtful’.
Difficulties in establishing causality assessments
with decisional algorithms are often due to the
presence of the so-called ‘confounding variables’.
‘Confounding occurs when the estimate of a measure
of association between drug exposure and health status
is distorted by the effect of one or several other
variables that are also risk factors for the outcome of
interest’.45 Confounding variables included character-
istics of adverse events which distorted (strengthen or
weaken) the association between a given algorithm
imputation and the ‘Gold Standard’ (compromising
algorithms validity), measured by their agreement,
because they made the two methods unadjusted
concerning information assessed and its relative
ponderation. Confounding variables were considered
as: underlying disease, concomitant use of other drugs,
absence of bibliographic description, dechallenge
with simultaneous treatment, unknown dechallenge,
absence of dechallenge, negative dechallenge, dechal-
lenge with simultaneous withdrawn of concomitant
drugs, unknown challenge and negative challenge. In
order to evaluate the influence of such variables on the
concordance between GI method and algorithms, ADR
reports were further evaluated and grouped according
to the presence of confounding variables. Concordance
between algorithms and GI method was also performed
within groups.
RESULTS
According to the expert panel, 29 cases were classified
as Definitive, 77 as Probable, 59 as Possible and 5 as
Unlikely; 18 reports were under follow-up evaluation,
therefore being classified as Conditional, while the
presence of insufficient or contradictory information
lead to 12 Unclassifiable cases. Results of compari-
sons between causality assessments from the GI
method and decisional algorithms are presented on
Table 2. For the total sample (200 ADR reports),
observed agreements between the GI method and
decisional algorithms varied from 21% (Co) to 56%T
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(Ki), the average being 47%, although agreements
beyond what would be expected by chance varied
from very low and not statistically different from
chance with Cornelli algorithm (¼ 0.005), to fair
agreement (¼ 0.36; p< 0.05) with Kitaguchi algo-
rithm, the average kappa being 0.26.
When confounding variables were taken into
account, three groups were found: group A (ADR’s
reports without any confounding variable, n¼ 54),
group B (ADR’s reports were definitive information on
confounding variables could not be collected, n¼ 26)
and group C (ADR’s reports with at least one
confounding variable, n¼ 120). For Group A observed
agreements varied between 41% (Co and W) and 69%
(Ki), the average being 58%, with poor and not
statistically different from chance agreement (¼ 0.00
and ¼ 0.02) with Stephens and Cornelli algorithms
and fair agreement (¼ 0.38; p< 0.05) with Kitaguchi
algorithm, the average kappa being 0.21. The kappa
statistic was not computed for Irey algorithm because
this method assessed Group A reports into a single
category of causality.
For Groups B and C observed results varied from,
respectively, 8% (¼0.05) (Co) to 65% (¼ 0.44;
p< 0.05) (Em) with an average of 46% observed
agreement and from 15% (¼0,02) (Co) to 53%
(¼ 0.27; p< 0.05) (I), with an average of 42%
observed agreement.
DISCUSSION AND CONCLUSIONS
The GI method was selected as the standard for
comparisons in the absence of a well established gold
standard. Its internal validity lies on the small prob-
ability of different results in the consensus obtained
for similar conditions, whilst its external validity
remains to be studied.
The extent of agreement between decisional algo-
rithms and GI was analysed using the kappa statistic.
This quantifies the extent to which the observed
proportion of agreements exceeds the proportion of
agreements we would expect by chance alone.46
Full agreement with GI was not found for any
algorithm. A large range of results was found amongst
algorithms providing evidence that they are not
interchangeable.
The overall observed agreement between algorithms
and GI was moderate (average 47%), although poorly
different from chance (average ¼ 0.26). In the
absence of confounding variables, agreements in the
observed results were found to be high when compared
to the total sample but for Dangoumau, Kramer,
Naranjo, Australian, Weber, Cornelli, Stephens andT
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Venulet algorithms such difference on degree of
agreement might be due to chance, considering the
reduction in kappa values. Confounding variables were
found to compromise algorithms ability to establish
causality of reported ADR’s by decreasing the
observed concordance of their results with those
obtained from an expert panel using the GI method
and increasing the extent of agreement expected as a
result of chance.
The algorithms presenting the highest levels of
observed agreement were also the one’s expressing the
highest agreement beyond chance. This was also found
when comparisons between groups were analysed.
Kitaguchi, Emanueli and Kramer algorithms were
found to provide the best global agreements with GI
method even in the presence of confounding variables.
Cornelli, Stephens and Weber judges agreed with GI
less often than chance would predict. These algorithms
do not offer advantages in the causality assessment
process.
In the light of the present findings, the value of
decisional algorithms in the assessment of ADR’s
causality remains to be established, confounding
variables being a shortcoming of their usefulness.
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